Immunotherapeutic Approved for Fourth Cancer Type
The FDA expanded the use of the immunotherapeutic pembrolizumab to include the treatment of certain patients with Hodgkin lymphoma.
Progress Against Cancer
The FDA expanded the use of the immunotherapeutic pembrolizumab to include the treatment of certain patients with Hodgkin lymphoma.
A molecularly targeted therapeutic was approved for use in combination with any aromatase inhibitor for the treatment of postmenopausal women with a certain form of breast cancer.
Study reports that cancer type and mortality differs among ethnic groups, suggesting a need for targeted public health efforts. A new study suggests that the growing Hispanic population in the United States may experience...
A study suggests that diet during adolescence and early adulthood may be associated with premenopausal breast cancer risk.
Study: Women who have a false-positive screening mammogram are more likely to delay their next breast cancer screening.
The FDA expanded the use of a targeted therapy for a form of non-Hodgkin lymphoma called marginal zone lymphoma.
An immune checkpoint inhibitor – a form of immunotherapy – has had its use expanded for use in the treatment of bladder cancer.
A study involving normal-weight postmenopausal women found that poor metabolic health was associated with an increased risk for colorectal cancer
Improving the rates of cervical cancer screening and HPV vaccination could have significant benefits on this form of cancer.
Research provides insight into the number of lives that could be saved if people under 18 were banned from using indoor UV tanning devices.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More